Zurich, Switzerland – September 9th, 2025 – cellvie, a company pioneering therapeutics based on mitochondria, today announced the closing of a $5 million funding round, with participation from both existing and new investors. The round was led by Taiho Ventures, with major contributions from Kizoo Technology Capital, an existing investor, and Beiersdorf Venture Capital.
The fresh capital will enable cellvie to accelerate the clinical translation of its lead program in kidney transplantation, and to further hone its pipeline. A major share of the proceeds is earmarked for the transfer of the company’s proprietary mitochondria preparation process to a professional manufacturing partner to enable production under Good Manufacturing Practice (GMP) – a prerequisite for starting a clinical trial.